PTC Therapeutics, Inc.
vatiquinone
Friedreich’s ataxia
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
An FDA complete response letter on vatiquinone for Friedreich’s ataxia is in focus around ~ Sep 30, 2026.
Primary source
· SEC 8-K
verified 12h ago
“Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback”